– Preclinical data demonstrates the potential for improved treatment outcomes and reduced toxicity for patients with AML –

–临床前数据表明，AML患者有可能改善治疗效果并降低毒性–

– Data supports the design of Phase 1 clinical trial of SENTI-202 with patient dosing anticipated in the second quarter of 2024 –

–数据支持SENTI-202第一阶段临床试验的设计，预计患者剂量将在2024年第二季度-

SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the publication of preclinical data demonstrating the ability of natural killer (NK) cells engineered with multi-input Gene Circuits to selectively target and eliminate leukemic cells, including both blasts and leukemic stem cells, while sparing healthy stem cells.

加利福尼亚州南旧金山，2024年4月30日（环球通讯社）--Senti Biosciences，Inc.（纳斯达克：SNTI）（“Senti Bio”）是一家利用其专有基因电路平台开发下一代细胞和基因疗法的生物技术公司，今天宣布发布临床前数据，证明用多输入基因电路设计的自然杀伤（NK）细胞能够选择性靶向和消除白血病细胞，包括原始细胞和白血病干细胞，同时保留健康的干细胞。

The data was published in Cell Reports on April 25, 2024..

该数据于2024年4月25日发表在Cell Reports上。。

The publication, titled “Precision off-the-shelf natural killer cell therapies for oncology with logic-gated gene circuits,” demonstrates the activity of logic-gated NK cells in vitro and in vivo preclinical studies.

该出版物题为“具有逻辑门控基因电路的肿瘤学精确现成自然杀伤细胞疗法”，展示了逻辑门控NK细胞在体外和体内临床前研究中的活性。

“AML, an aggressive form of leukemia with a poor prognosis, has long presented a challenge for targeted therapies due to the lack of a single tumor-associated antigen that distinguishes cancer cells from healthy cells,” said Timothy Lu, MD, PhD, Chief Executive Officer and Co-Founder of Senti Bio. “By harnessing the power of logic-gated NK cells, this preclinical data demonstrates SENTI-202’s ability to precisely target and eliminate leukemic cells while sparing healthy stem cells, thereby illustrating the potential to minimize the risk of harmful side effects and maximizing the potential for deep therapeutic efficacy.

Senti Bio首席执行官兼联合创始人Timothy Lu博士说：“AML是一种预后不良的侵袭性白血病，由于缺乏区分癌细胞和健康细胞的单一肿瘤相关抗原，长期以来对靶向治疗提出了挑战。”通过利用逻辑门控NK细胞的力量，这些临床前数据证明了Senti-202能够精确靶向和消除白血病细胞，同时保留健康干细胞，从而说明了尽可能减少有害副作用风险并最大限度地发挥深层治疗功效的潜力。

We are encouraged about the possibility of translating these findings into our Phase 1 clinical trial of SENTI-202, which is on track to begin this quarter, offering new hope for patients with limited options today.'.

我们对将这些发现转化为我们的SENTI-202第一阶段临床试验的可能性感到鼓舞，该试验有望于本季度开始，为今天选择有限的患者提供了新的希望。”。

The peer-reviewed publication describes preclinical studies of engineered NK cells with a Gene Circuit consisting of chimeric antigen receptors (CARs) controlled by OR and NOT logic gates. This approach allows NK cells to detect and respond to multiple antigen inputs, enabling precise targeting of AML cells while protecting healthy cells.

同行评审的出版物描述了工程化NK细胞的临床前研究，其基因电路由OR和NOT逻辑门控制的嵌合抗原受体（CAR）组成。这种方法允许NK细胞检测并响应多种抗原输入，从而能够精确靶向AML细胞，同时保护健康细胞。

Using the OR gate, NK cells were able to kill a range of AML cells, including leukemic stem cells and blasts, by recognizing FLT3 and/or CD33, which are validated therapeutic targets for AML. The NOT gate component of the Gene Circuit protected healthy HSCs by reducing CAR-mediated killing through an inhibitory CAR recognizing the endomucin antigen, which is selectively expressed on healthy HSCs but not cancer cells.

使用OR门，NK细胞能够通过识别FLT3和/或CD33来杀死一系列AML细胞，包括白血病干细胞和原始细胞，FLT3和/或CD33是AML的有效治疗靶点。基因回路的非门成分通过识别内切粘蛋白抗原的抑制性CAR减少CAR介导的杀伤来保护健康的HSC，内切粘蛋白抗原在健康的HSC而非癌细胞上选择性表达。

In preclinical mouse models, the engineered NK cells killed multiple AML subtypes while protecting primary hematopoietic stem cells (HSCs)..

在临床前小鼠模型中，工程化的NK细胞杀死多种AML亚型，同时保护原代造血干细胞（HSC）。。

This data supports the design of Phase 1 clinical trial of SENTI-202, a potential first-in-class, off-the-shelf logic-gated CAR-NK investigational cell therapy for the treatment of AML. Senti Bio is on track to initiate patient dosing in the second quarter of 2024, with initial efficacy data anticipated by year-end 2024 and initial durability data following in 2025..

该数据支持SENTI-202的1期临床试验的设计，SENTI-202是一种潜在的一流，现成的逻辑门控CAR-NK研究性细胞疗法，用于治疗AML。Senti Bio有望在2024年第二季度开始患者给药，预计2024年底将有初步疗效数据，2025年将有初步耐久性数据。。

About Senti Bio

关于Feel Bio

Senti Biosciences is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging a synthetic biology platform called Gene Circuits to create therapies with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, spare healthy cells, increase specificity to target cells and control the expression of drugs even after administration.

Senti Biosciences是一家生物技术公司，为患有不治之症的患者开发新一代细胞和基因疗法。为了实现这一目标，Senti Bio正在利用一个称为基因电路的合成生物学平台来创建具有更高精度和控制能力的疗法。这些基因电路旨在精确杀死癌细胞，保留健康细胞，增加对靶细胞的特异性，甚至在给药后也能控制药物的表达。

The Company’s wholly-owned pipeline utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells, outfitted with Gene Circuits, to target challenging liquid and solid tumor indications. Senti Bio has also preclinically demonstrated the potential breadth Gene Circuits in other modalities, diseases outside of oncology, and continues to advance these capabilities through partnerships with Spark Therapeutics and BlueRock Therapeutics..

该公司的全资管道利用现成的嵌合抗原受体自然杀伤（CAR-NK）细胞，配备基因电路，针对具有挑战性的液体和固体肿瘤适应症。Senti Bio也在临床前证明了其他方式，肿瘤学以外的疾病中潜在的广度基因回路，并通过与Spark Therapeutics和BlueRock Therapeutics的合作伙伴关系继续提高这些能力。。

Forward-Looking Statements

前瞻性声明

This press release and document contain certain statements that are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally are identified by the words “believe,” “could,” “predict,” “continue,” “ongoing,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” “forecast,” “seek,” “target” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters.

本新闻稿和文件包含某些非历史事实的陈述，被视为1933年《证券法》第27A节（修订版）和1934年《证券交易法》第21E节（修订版）所指的前瞻性陈述。这些前瞻性陈述通常由“相信”、“可以”、“预测”、“继续”、“正在进行”、“项目”、“期望”、“预期”、“估计”、“打算”、“战略”、“未来”、“机会”、“计划”、“可能”、“应该”、“将会”、“将会”、“将会继续”、“将可能产生”、“预测”、“寻求”、“目标”以及预测或指示未来事件或趋势或不属于历史事项陈述的类似表达来识别。

Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations of Senti Bio’s management and assumptions, whether or not identified in this document, and, as a result, are subject to risks and uncertainties. Forward-looking statements include, but are not limited to; expectations regarding its growth, strategy, progress and timing of its preclinical studies, including SENTI-202, and clinical trials, including the anticipated dosing of patients and availability of data, and the timing thereof; the ability of any product candidate to perform in humans in a manner consistent with earlier nonclinical, preclinical or clinical trial data; and the ability to initiate new clinical programs.

前瞻性陈述是基于Senti Bio管理层当前预期和假设的关于未来事件的预测、预测和其他陈述，无论本文件是否确定，因此都会受到风险和不确定性的影响。前瞻性声明包括但不限于：；对其临床前研究（包括SENTI-202）和临床试验（包括预期的患者剂量和数据可用性）的增长，策略，进展和时间安排的预期；任何候选产品以与早期非临床，临床前或临床试验数据一致的方式在人体内表现的能力；以及启动新临床计划的能力。

These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as, a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficul.

这些前瞻性陈述仅用于说明目的，不打算也不可被任何投资者作为担保、保证、预测或事实或概率的最终陈述。实际事件和情况都很困难。

Availability of Other Information About Senti Biosciences, Inc.

有关Senti Biosciences，Inc.的其他信息的可用性。

For more information, please visit the Senti Bio website at https://www.sentibio.com or follow Senti Bio on Twitter (@SentiBio) and LinkedIn (Senti Biosciences). Investors and others should note that we communicate with our investors and the public using our company website (www.sentibio.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on Twitter and LinkedIn.

有关更多信息，请访问Senti Bio网站https://www.sentibio.com或者在Twitter（@SentiBio）和LinkedIn（Senti Biosciences）上关注Senti Bio。投资者和其他人应注意，我们使用公司网站（www.sentibio.com）与投资者和公众进行沟通，包括但不限于公司披露、投资者介绍和常见问题解答、证券交易委员会备案、新闻稿、公开电话会议记录和网络广播记录，以及推特和LinkedIn。

The information that we post on our website or on Twitter or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended..

我们在网站、推特或LinkedIn上发布的信息可能被视为重要信息。因此，我们鼓励投资者、媒体和其他有兴趣的人定期审查我们在那里发布的信息。我们网站或社交媒体的内容不应被视为通过引用纳入1933年《证券法》修订版下的任何备案中。。

Senti Bio Contacts

感觉生物联系人

Investors: investors@sentibio.com

投资者：investors@sentibio.com

Media: media@sentibio.com

媒体media@sentibio.com